Gene Fusion Products For Therapeutic Drug Development Essay

1479 Words 6 Pages
Deliverables for Specific Aim 2: Any candidate gene identified in AA PCa will be subjected to screening EA PCa cohort. Depending on the nature of the candidate gene we will choose PCR, FISH, IHC and RNA-ISH approach to study the recurrent nature. Our systematic analysis of sequencing data we will address the following questions: Among the many fusion genes in a sample, how many of them are causal aberrations (driver)? How many of them are responsible for tumor growth (passenger)? How do so many abnormal gene fusion products cooperate in a tumor environment? Do they function in a common signaling pathway? The different clinical outcome and available treatment options for each molecular subtype will lead to the development of new diagnostic methods and reagents for the accurate diagnosis of prostate cancer. The new prostate cancer classification system will be based on molecular aberrations rather than its morphological and histological subtypes. This line of inquiry will lay the foundation for treatment strategies and targeting gene fusion products for therapeutic drug development.
Potential pitfalls and alternative strategies for Specific Aim 2: As discussed above we are employing a calculated strategy to maximize the chances of discovering new molecular markers by systematically weeding out samples and select only that are negative for any of the known makers. Next generation paired-end transcriptome sequencing is a well-established platform particularly Illumina sequencing…

Related Documents